IL24 and hepatocellular carcinoma: An Ad expressing both MDA-7/IL-24 and miRNA-34a under an endogenous E3 promoter displayed higher antitumor activity than the individual therapeutic activity of these molecules when used alone in hepatocarcinoma (HCC) cells [44].